NCT01488344View on ClinicalTrials.gov

Phase I/II Trial: BIBF 1120 Added to Low-dose Cytarabine in Elderly Patients With Acute Myeloid Leukemia (AML)

PHASE1/PHASE2UnknownINTERVENTIONAL

Enrollment

140

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

November 30, 2014

Conditions

Acute Myeloid Leukemia

Interventions

DRUG

triple kinase inhibitor BIBF1120

triple kinase inhibitor BIBF1120 is given in addition to low-dose cytarabine

Trial Locations (1)

48149

Universitätsklinikum Münster, Medizinische Klinik und Poliklinik A, Münster

Sponsors

Collaborators (1)

Boehringer Ingelheim

All Listed Sponsors

collaborator

Boehringer Ingelheim

INDUSTRY

lead

University Hospital Muenster

OTHER

NCT01488344 - Phase I/II Trial: BIBF 1120 Added to Low-dose Cytarabine in Elderly Patients With Acute Myeloid Leukemia (AML) | Biotech Hunter | Biotech Hunter